Bleakley Financial Group LLC Raises Stake in Sanofi (NASDAQ:SNY)

Bleakley Financial Group LLC boosted its position in Sanofi (NASDAQ:SNY) by 3.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 120,631 shares of the company’s stock after buying an additional 4,190 shares during the period. Bleakley Financial Group LLC’s holdings in Sanofi were worth $6,952,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Stablepoint Partners LLC lifted its holdings in Sanofi by 0.8% in the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after acquiring an additional 189 shares during the period. TCTC Holdings LLC lifted its holdings in Sanofi by 28.0% in the first quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after acquiring an additional 210 shares during the period. HB Wealth Management LLC lifted its holdings in Sanofi by 3.7% in the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after acquiring an additional 221 shares during the period. Wynn Capital LLC lifted its holdings in Sanofi by 4.5% in the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock valued at $256,000 after acquiring an additional 226 shares during the period. Finally, Insigneo Advisory Services LLC lifted its holdings in Sanofi by 3.3% in the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock valued at $371,000 after acquiring an additional 228 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 0.8 %

Shares of SNY stock opened at $54.86 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $139.21 billion, a price-to-earnings ratio of 29.82, a PEG ratio of 1.57 and a beta of 0.60. The stock has a 50 day simple moving average of $56.05 and a 200-day simple moving average of $51.48. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same period in the prior year, the company earned $0.95 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts expect that Sanofi will post 4.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SNY. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.